JP5535616B2 - 口腔内崩壊錠剤のための直接圧縮性複合材 - Google Patents

口腔内崩壊錠剤のための直接圧縮性複合材 Download PDF

Info

Publication number
JP5535616B2
JP5535616B2 JP2009502338A JP2009502338A JP5535616B2 JP 5535616 B2 JP5535616 B2 JP 5535616B2 JP 2009502338 A JP2009502338 A JP 2009502338A JP 2009502338 A JP2009502338 A JP 2009502338A JP 5535616 B2 JP5535616 B2 JP 5535616B2
Authority
JP
Japan
Prior art keywords
agent
hydrochloride
agents
orally disintegrating
calcium silicate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009502338A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532343A5 (https=
JP2009532343A (ja
Inventor
プラティバ エス． ピルガオンカー，
マハルク ティー． ルストムジー，
アニルクマー エス． ガンジー，
プラドニヤ バグデ，
ヘタール エヌ． モルベカー，
Original Assignee
ルビコン リサーチ プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルビコン リサーチ プライベート リミテッド filed Critical ルビコン リサーチ プライベート リミテッド
Publication of JP2009532343A publication Critical patent/JP2009532343A/ja
Publication of JP2009532343A5 publication Critical patent/JP2009532343A5/ja
Application granted granted Critical
Publication of JP5535616B2 publication Critical patent/JP5535616B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009502338A 2006-03-31 2007-03-30 口腔内崩壊錠剤のための直接圧縮性複合材 Expired - Fee Related JP5535616B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN498MU2006 2006-03-31
IN498/MUM/2006 2006-03-31
PCT/IN2007/000138 WO2007113856A2 (en) 2006-03-31 2007-03-30 Directly compressible composite for orally disintegrating tablets

Publications (3)

Publication Number Publication Date
JP2009532343A JP2009532343A (ja) 2009-09-10
JP2009532343A5 JP2009532343A5 (https=) 2010-04-02
JP5535616B2 true JP5535616B2 (ja) 2014-07-02

Family

ID=38562805

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009502338A Expired - Fee Related JP5535616B2 (ja) 2006-03-31 2007-03-30 口腔内崩壊錠剤のための直接圧縮性複合材

Country Status (13)

Country Link
US (2) US20090208576A1 (https=)
EP (1) EP2001450B1 (https=)
JP (1) JP5535616B2 (https=)
KR (1) KR101324898B1 (https=)
CN (1) CN101460150B (https=)
AU (1) AU2007232098A1 (https=)
BR (1) BRPI0709909A2 (https=)
CA (1) CA2650498A1 (https=)
IL (1) IL194355A0 (https=)
MX (1) MX2008012299A (https=)
NO (1) NO20084612L (https=)
NZ (1) NZ572106A (https=)
WO (1) WO2007113856A2 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US9198862B2 (en) * 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090208576A1 (en) 2006-03-31 2009-08-20 Gandhi Anilkumar S Orally Disintegrating Tablets
US20100092564A1 (en) * 2006-12-21 2010-04-15 Jae Han Park Composition of and Method for Preparing Orally Disintegrating Tablets
HUP0700485A3 (en) * 2007-07-23 2010-01-28 Richter Gedeon Nyrt Pharmaceutical composition with controlled release containing tolperisone
BRPI0817927A2 (pt) 2007-10-01 2015-04-07 Lesvi Laboratorios Sl Comprimidos orodispersiveis
US20100215740A1 (en) * 2007-10-10 2010-08-26 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009078034A2 (en) * 2007-11-26 2009-06-25 Rubicon Research Private Limited Oral disintegrating tablets of ropinirole hydrochloride
JP4989733B2 (ja) * 2008-02-13 2012-08-01 大日本住友製薬株式会社 口腔内崩壊錠
KR101075556B1 (ko) * 2008-11-21 2011-10-20 씨제이제일제당 (주) 구강내 속붕해정 및 그 제조방법
EP2198857A1 (en) 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
US20100179202A1 (en) * 2009-01-14 2010-07-15 Ajanta Pharma Limited. Orally disintegrating composition of zolmitriptan
EP2398468B1 (en) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
US20120004321A1 (en) * 2009-03-16 2012-01-05 Nipro Corporation Orally Disintegrating Tablet
US20120178822A1 (en) * 2009-04-28 2012-07-12 Isp Investments Inc. Co-Processed Excipient Compositions
JP5458096B2 (ja) 2009-05-20 2014-04-02 大日本住友製薬株式会社 有核型の口腔内崩壊錠
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2011001214A1 (en) * 2009-06-30 2011-01-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Surface amorphization of phenprobamate
JP6038651B2 (ja) * 2009-07-10 2016-12-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 錠剤を製造するための組成物の調製方法
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
CA2773003A1 (en) * 2009-09-15 2011-03-24 Ratiopharm Gmbh Orally disintegrating pharmaceutical dosage form containing aripiprazole
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
EP2316434A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of memantine
CN103284968B (zh) * 2010-04-13 2015-11-18 齐鲁制药有限公司 一种阿立哌唑组合物微晶的口腔崩解片及其制备方法
EP2384742A1 (en) 2010-05-03 2011-11-09 The Jordanian Pharmaceutical Manufacturing Co. Pharmaceutical excipient, method for its preparation and use thereof
JP5665372B2 (ja) * 2010-06-02 2015-02-04 旭化成ケミカルズ株式会社 速崩壊性固形製剤
US20110300216A1 (en) * 2010-06-03 2011-12-08 First Eric R Chewable, swallowable and effervescent solid dosage form for oral delivery of pharmaceutical actives
US8883788B2 (en) * 2010-08-04 2014-11-11 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
EP2627323A4 (en) 2010-10-12 2014-03-12 Univ Johns Hopkins HUSTENSTILLENDE COMPOSITIONS WITH MEMANTINE
EP2468254A1 (en) * 2010-12-15 2012-06-27 Hexal AG Orally disintegrating tablet having a taste masking effect
WO2013019056A1 (en) * 2011-08-01 2013-02-07 Sam-A Pharm. Co., Ltd. Novel granule formulation containing sildenafil or pharmaceutically acceptable salts thereof as an active ingredient
EP2760417B1 (en) * 2011-09-30 2020-11-11 Rubicon Research Private Limited Oral care compositions
WO2013058721A1 (en) * 2011-10-13 2013-04-25 Mahmut Bilgic Pharmaceutical granules and production method
CN102525978B (zh) * 2012-02-07 2013-08-07 海南卫康制药(潜山)有限公司 小儿阿莫西林克拉维酸钾组合物
CN104159583B (zh) * 2012-02-22 2018-04-13 富山化学工业株式会社 含有1‑(3‑(2‑(1‑苯并噻吩‑5‑基)乙氧基)丙基)氮杂环丁烷‑3‑醇或其盐的固体药物组合物
US20130274342A1 (en) * 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
CN102631331A (zh) * 2012-04-26 2012-08-15 北京哈三联科技股份有限公司 奥氮平口腔崩解片制剂及其制备方法
CN104244931A (zh) * 2012-04-27 2014-12-24 默克专利股份有限公司 经包衣的片剂及其制备
CN103385859A (zh) * 2012-05-08 2013-11-13 中国人民解放军成都军区总医院 一种治疗创伤后应激障碍症的盐酸普萘洛尔口腔崩解片及其制备方法
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
WO2014007775A1 (en) * 2012-07-02 2014-01-09 Mahmut Bilgic A novel formulation having fast dissolution
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
FR2999432B1 (fr) * 2012-12-17 2014-12-12 Ethypharm Sa Comprimes orodispersibles obtenus par compression moulage
CN103127024B (zh) * 2013-03-12 2014-10-15 成都天台山制药有限公司 稳定的三磷酸腺苷二钠片剂
MX365513B (es) 2013-03-15 2019-06-06 Aprecia Pharmaceuticals LLC Forma de dosificacion de dispersion rapida que contiene levetiracetam.
GR1008186B (el) * 2013-04-22 2014-05-08 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
ES2908977T3 (es) * 2013-06-03 2022-05-04 Mcneil Ab Forma de dosificación farmacéutica sólida para liberar en la cavidad oral al menos dos ingredientes farmacéuticos activos
EP3023109A4 (en) 2013-07-19 2017-01-04 Sanwa Kagaku Kenkyusho Co., Ltd Orally disintegrating tablet
KR101428018B1 (ko) * 2013-10-18 2014-08-12 주식회사 한독 아리피프라졸 함유 구강 붕해 정제 및 이의 제조 방법
WO2015072602A1 (ko) * 2013-11-15 2015-05-21 (주)다미화학 난용성 물질의 수용액 가용화 조성물 및 이를 이용한 난용성 물질의 수용액 가용방법
US20150157660A1 (en) * 2013-12-10 2015-06-11 Lifewave, Inc. Nutritional product composition for energy
AU2015237721B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
CN104027319A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 一种塞来昔布分散片及其制备方法
SG11201702069XA (en) * 2014-09-24 2017-04-27 Wellesley Pharmaceuticals Llc Pharmaceutical formulation for reducing bladder spasms and method of use thereof
CN104490832A (zh) * 2014-12-05 2015-04-08 海南卫康制药(潜山)有限公司 一种华法林组合物冻干片及其制备方法
DE202016008304U1 (de) 2015-01-22 2017-07-05 Pfeifer & Langen GmbH & Co. KG Cellobiose in Zusammensetzungen zum Verzehr oder zur Einnahme
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CN105935445B (zh) * 2016-03-28 2019-02-01 赤峰赛林泰药业有限公司 含2-(-4-异丁基苯基)丙酸右旋物的药物组合物及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TR201617675A2 (tr) 2016-12-02 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Ari̇pi̇prazole monohi̇drat formülasyonlarinin ağizda dağilan tablet formu
JP6838474B2 (ja) * 2017-04-14 2021-03-03 大正製薬株式会社 固形組成物
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CN107334744B (zh) * 2017-07-24 2020-09-04 湖南洞庭药业股份有限公司 盐酸美金刚药物组合物和制法
CN109806232A (zh) * 2017-11-20 2019-05-28 四川科瑞德制药股份有限公司 盐酸替扎尼定口崩片及其制备方法
CN110613691A (zh) * 2018-06-19 2019-12-27 北京万全德众医药生物技术有限公司 一种含有peg-dspe-盐酸美金刚复合物的口崩片
JP2019069991A (ja) * 2018-12-27 2019-05-09 ウェルズリー ファーマスーティカルズ、エルエルシー 膀胱痙攣を低減するための医薬製剤およびその使用の方法
RS64615B1 (sr) * 2019-01-15 2023-10-31 Dr Willmar Schwabe Gmbh & Co Kg Proces za proizvodnju tableta jednostavnih za uzimanje sa suvim ekstraktom iz listova ginko bilobe
CN109975461B (zh) * 2019-04-10 2022-03-22 中生北控生物科技股份有限公司 维生素d及其代谢物的质谱检测用校准品和质控品及其制备方法和应用
CN111419816A (zh) * 2020-04-28 2020-07-17 广东润源中天生物科技有限公司 一种b族维生素片剂及其生产方法
RS63725B1 (sr) 2020-05-18 2022-12-30 Orexo Ab Nova farmaceutska kompozicija za davanje leka
CN111838663A (zh) * 2020-08-05 2020-10-30 田井文 一种食药两用的壮阳补肾中药组合物及其制备方法
JP2024529727A (ja) * 2021-08-19 2024-08-08 マインド メディシン， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤
CN113712926A (zh) * 2021-08-31 2021-11-30 南京恒正药物研究院有限公司 一种西地那非口崩片
JP2024541322A (ja) * 2021-11-16 2024-11-08 ディーエスエム アイピー アセッツ ビー．ブイ． 連続溶融造粒により取得できる顆粒
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
CN115089552B (zh) * 2022-06-10 2024-03-29 南京瑞捷医药科技有限公司 一种布洛芬口腔崩解片
USD1080854S1 (en) * 2022-12-13 2025-06-24 Church & Dwight Co., Inc. Oral product
US20240408042A1 (en) * 2023-06-08 2024-12-12 Clinical Research Associates LLC Orally disintegrating baclofen compositions and methods of making same
MX2023008370A (es) * 2023-07-13 2025-02-10 Posi Visionary Solutions Llp Composicion farmaceutica orodispersable de clonazepam
GB2644313A (en) * 2024-09-27 2026-04-01 Novumgen Ltd An orodispersible tablet of Famotidine and its process of preparation

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4480068A (en) 1981-09-14 1984-10-30 Fiberglas Canada Inc. High temperature resistant binders
US4719181A (en) 1985-12-20 1988-01-12 Warner-Lambert Company Free flowing granular indicator material for peroxidase-like activity
US4906478A (en) 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
WO1991004757A1 (en) 1989-10-02 1991-04-18 Cima Labs, Inc. Effervescent dosage form and method of administering same
DK546289D0 (da) 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
DE4439858A1 (de) 1994-11-08 1996-05-09 Merck Patent Gmbh Durch Co-Sprühtrocknung erhältliche Polyol-Zusammensetzung
JP2000507587A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼ阻害剤
DE19615418A1 (de) 1996-04-22 1997-10-23 Merck Patent Gmbh Polyol-Zusammensetzung
DK0914818T3 (da) 1996-06-14 2005-07-04 Kyowa Hakko Kogyo Kk Intraoralt hurtigt desintegrerbar tablet
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
JP4494539B2 (ja) 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． 流動自由な乾燥粒子
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
JPH11302157A (ja) 1998-04-17 1999-11-02 Eisai Co Ltd 口腔内速崩壊性錠剤
DK2263660T3 (en) 1998-05-18 2018-01-02 Takeda Pharmaceuticals Co Orally disintegrating tablets.
WO2000003735A1 (fr) 1998-07-15 2000-01-27 Asahi Kasei Kogyo Kabushiki Kaisha Excipient
ATE291418T1 (de) 1998-07-28 2005-04-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
JP2000086537A (ja) 1998-09-11 2000-03-28 Fuji Chem Ind Co Ltd 無機化合物糖類組成物、賦形剤、速崩壊性圧縮成型物及びその製造方法
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
US6740339B1 (en) 1999-06-18 2004-05-25 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
DE60134855D1 (de) 2000-06-30 2008-08-28 Procter & Gamble Orale zubereitungen, die antimikrobielle wirkstoffe enthalten zur prävention von systemischen erkrankungen
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
JPWO2002069934A1 (ja) 2001-03-06 2004-07-02 協和醗酵工業株式会社 口腔内速崩壊性製剤
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
US6610266B2 (en) * 2001-11-28 2003-08-26 Michael C. Withiam Calcium metasilicates and methods for making
DE10161402A1 (de) 2001-12-13 2003-06-18 Merck Patent Gmbh Verfahren zur Herstellung von direkt tablettierbarem beta-Mannit
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
JP4551092B2 (ja) * 2002-03-06 2010-09-22 協和発酵キリン株式会社 口腔内速崩壊性錠剤
US6738873B2 (en) 2002-05-24 2004-05-18 Sun Microsystems, Inc. Memory management system supporting deletion of transient objects
WO2004033088A1 (ja) 2002-10-08 2004-04-22 Mitsubishi Gas Chemical Company, Inc. 脱酸素剤組成物
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
KR101099176B1 (ko) 2003-01-21 2011-12-27 니뽄 신야쿠 가부시키가이샤 구강내 속붕성 정제
FR2851734B1 (fr) 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
WO2004082664A1 (en) 2003-03-21 2004-09-30 Ranbaxy Laboratories Limited Water-soluble tablets of metformin
KR100503949B1 (ko) 2003-04-28 2005-07-26 주식회사유한양행 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
IN2003MU00504A (https=) * 2003-06-05 2005-05-13 Alembic Ltd
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
US8647668B2 (en) * 2003-10-15 2014-02-11 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
WO2005051349A2 (en) * 2003-11-25 2005-06-09 Aurobindo Pharma Ltd. Pharmaceutical compositions of mirtazapine
EP1732527A2 (en) * 2004-03-17 2006-12-20 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US20070196475A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly disintegrating low friability tablets comprising silica materials
JP2006052167A (ja) * 2004-08-11 2006-02-23 Rohto Pharmaceut Co Ltd 錠剤組成物
WO2006035313A1 (en) * 2004-09-29 2006-04-06 Aurobindo Pharma Ltd Solid unit dosage forms of 5-ht1 agonist
EP1681048A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Orally disintegrating composition of olanzapine or donepezil
KR20140065482A (ko) 2005-03-24 2014-05-29 다이이찌 산쿄 가부시키가이샤 의약용 조성물
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
AU2006283121A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
WO2007097333A1 (ja) 2006-02-20 2007-08-30 Asahi Breweries, Ltd. 顆粒、錠剤およびそれらの製造方法
US20090208576A1 (en) 2006-03-31 2009-08-20 Gandhi Anilkumar S Orally Disintegrating Tablets
US20070243248A1 (en) 2006-04-14 2007-10-18 Cherukuri S Rao Rapidly disintegrating solid oral dosage form of liquid dispersions
US20100055179A1 (en) 2006-12-21 2010-03-04 Mallinckrodt Inc. Composition of and Method for Preparing Orally Disintegrating Tablets Containing a High Dose of Pharmaceutically Active Ingredients

Also Published As

Publication number Publication date
EP2001450A2 (en) 2008-12-17
CN101460150A (zh) 2009-06-17
MX2008012299A (es) 2008-11-18
EP2001450B1 (en) 2019-01-30
NO20084612L (no) 2008-10-31
US20090087485A1 (en) 2009-04-02
IL194355A0 (en) 2009-08-03
CN101460150B (zh) 2014-02-12
US20090208576A1 (en) 2009-08-20
KR101324898B1 (ko) 2013-11-04
US8545890B2 (en) 2013-10-01
BRPI0709909A2 (pt) 2011-07-26
WO2007113856A3 (en) 2008-06-05
NZ572106A (en) 2010-12-24
WO2007113856A2 (en) 2007-10-11
KR20090008307A (ko) 2009-01-21
CA2650498A1 (en) 2007-10-11
AU2007232098A1 (en) 2007-10-11
JP2009532343A (ja) 2009-09-10

Similar Documents

Publication Publication Date Title
JP5535616B2 (ja) 口腔内崩壊錠剤のための直接圧縮性複合材
KR101565621B1 (ko) 저치환도 히드록시프로필셀룰로오스 수분산액을 이용한 습식 조립 타정법
JP4920798B2 (ja) ２種以上の粒子を含有する口腔内速崩壊錠
JP2009114113A (ja) 口腔内崩壊錠及びその製造方法
WO2010061846A1 (ja) 口腔内速崩壊性錠及びその製造方法
US8425935B2 (en) Pharmaceutical formulation for producing rapidly disintegrating tablets
KR20030094272A (ko) 구강내 급속 붕괴성 정제
CN101677945A (zh) 坚固的快速崩解片剂制剂
WO2007074856A1 (ja) 口腔内崩壊性固形製剤の製造法
TW201206434A (en) Fexofenadine-based composition and preparation process therefor
KR20150056474A (ko) 복합 조립물 및 속방성 정제, 및 이들의 제조 방법
Nandy et al. An overview on fast dissolving drug delivery system
EP2745848B1 (en) Orally disintegrating tablet containing hydroxyalkyl cellulose fine particles
JP5572321B2 (ja) 被覆微粒子含有口腔内崩壊錠
A. AlHusban et al. Recent patents and trends in orally disintegrating tablets
CN101401796A (zh) 普拉克索口腔崩解片及其制备方法
WO2015050209A1 (ja) 錠剤の製造方法
JP5080856B2 (ja) 経口投与用錠剤
JP5801266B2 (ja) 疎水性薬物を含む錠剤製造方法
WO2013185789A1 (en) Pharmaceutical composition containing phosphate binding polymer
TW201609193A (zh) 含有碳酸鹽之口腔內崩解錠劑用組成物及口腔內崩解錠劑
KR20090113776A (ko) 경구 고형 조성물
HK1146387A (en) Oral dispersable tablet

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120713

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121015

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121015

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20121015

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130326

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140423

R150 Certificate of patent or registration of utility model

Ref document number: 5535616

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees